Cover Image

Obstretics Partnering 2007-2012

Notice
This publication has been discontinued on February 13, 2014.

‘Obstretics Partnering 2007-2012’ report provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in obstretics partnering deals
  • Top obstretics deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type

‘Obstretics Partnering 2007-2012’ provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of obstretics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstretics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 60 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of HIV partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in obstretics partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading obstretics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of obstretics partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of obstretics technologies and products.

Report scope

‘Obstretics Partnering 2007-2012’ is intended to provide the reader with an in-depth understanding and access to obstretics trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in obstretics dealmaking in the biopharma industry since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • The leading obstretics deals by value since 2007

In ‘Obstretics Partnering 2007-2012’, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits:

‘Obstretics Partnering 2007-2012’ provides the reader with the following key benefits:

  • In-depth understanding of obstretics deal trends since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 60 actual obstretics deals entered into by the world's biopharma companies since 2007
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in obstretics partnering

  • 2.1. Introduction
  • 2.2. Obstretics partnering over the years
  • 2.3. Bigpharma obstretics dealmaking activity
  • 2.4. Obstretics partnering by deal type
  • 2.5. Obstretics partnering industry sector
  • 2.6. Obstretics partnering by stage of development
  • 2.7. Obstretics partnering by technology type
  • 2.8. Disclosed financial deal terms for obstretics partnering
    • 2.8.1. Obstretics headline values
    • 2.8.2. Obstretics upfront payments
    • 2.8.3. Obstretics milestone payments
    • 2.8.4. Obstretics royalty rates

Chapter 3 - Leading obstretics deals

  • 3.1. Introduction
  • 3.2. Top obstretics deals by value
  • 3.3. Top obstretics deals involving bigpharma

Chapter 4 - Dealmaking directory

  • 4.1. Introduction
  • 4.2. Company A-Z
  • 4.3. By deal type
    • Asset purchase
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Contract service
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Manufacturing
    • Marketing
    • Option
    • Promotion
    • Research
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Termination
  • 4.4. By industry sector
    • Academic
    • Bigpharma
    • Biotech
    • Drug delivery
    • Medical device
    • Diagnostic
    • Generic pharma
    • Government
    • Non-profit
    • Pharmaceutical
    • Research tools
    • Services
    • Specialty pharma
  • 4.5. By stage of development
    • Discovery
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
    • Registration
    • Marketed
  • 4.6. By technology type
    • Analysis
    • Animal models
    • Assays
    • Bioinformatics
    • Biological compounds
    • Biomarkers
    • Biomaterials
    • Cell culture
    • Cell therapy
    • Clinical testing
    • Diagnostic - companion
    • Devices
    • Diagnostics
    • Discovery tools
    • DNA probes
    • Drug delivery
    • Enabling technology
    • Epigenetics
    • Equipment
    • Facilities
    • Gene therapy
    • Genomics
    • Imaging
    • Industrial chemicals
    • In vitro models
    • Monoclonal antibodies
    • Nanotechnology
    • Oligonucleotide
    • Peptides
    • Personalised medicine
    • Processes
    • Proteomics
    • Radio/Chemo-therapy
    • Recombinant DNA
    • Research services
    • Research supplies
    • RNA therapeutics
    • Screening
    • Small molecules
    • Stem cells
    • Vaccines

Chapter 5 - Partnering resource center

  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports

Table of figures

  • Figure 1: Obstretics partnering since 2007
  • Figure 2: Bigpharma - top 50 - obstretics deals 2007 to 2011
  • Figure 3: Bigpharma obstretics deal frequency - 2007 to 2011
  • Figure 4: Obstretics partnering by deal type since 2007
  • Figure 5: Obstretics partnering by industry sector since 2007
  • Figure 6: Obstretics partnering by stage of development since 2007
  • Figure 7: Obstretics partnering by technology type since 2007
  • Figure 8: Obstretics deals with a headline value
  • Figure 9: Obstretics deals with upfront payment values
  • Figure 10: Obstretics deals with milestone payments
  • Figure 11: Obstretics deals with royalty rates, %
  • Figure 12: Top obstretics deals by value since 2007
  • Figure 13: Top obstretics deals signed by bigpharma value since 2007
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions
Show More
Pricing
Not Available
Get Notified
Email me when related reports are published